Protein of vascular endothelial growth inhibitor 174 inhibits epithelial-mesenchymal transition in renal cell carcinoma in vivo

Zhao, Qiang, Deng, Xiaohu, Hong, Baoan, Wang, Feng, Tang, Xinxin, Yang, Yong, Gong, Kan, Ye, Lin ORCID: https://orcid.org/0000-0002-0303-2409, Jiang, Wen G. ORCID: https://orcid.org/0000-0002-3283-1111 and Zhang, Ning 2017. Protein of vascular endothelial growth inhibitor 174 inhibits epithelial-mesenchymal transition in renal cell carcinoma in vivo. Anticancer Research 37 (8) , pp. 4269-4275. 10.21873/anticanres.11819

Preview

PDF - Published Version Download (2MB) | Preview

Abstract

Background: Vascular endothelial growth inhibitor (VEGI) is a member of the tumor necrosis factor superfamily, identified as an anti-angiogenic cytokine. However, the effect of VEGI on epithelial–mesenchymal transition (EMT) in renal cell carcinoma (RCC) is still unknown. Materials and Methods: In this study, protein VEGI174 was designed and synthesized. Renal cell carcinoma A498 cells were implanted into immune-deficient mice to establish tumor models. Two groups were included: control group treated with saline, and VEGI174-treated group. Data of tumor growth were collected every 3 to 4 days. Two weeks later, the tumor specimens were harvested for immunohistochemical staining of EMT markers (E-cadherin, N-cadherin, vimentin). Results: Compared to the saline-treated group, the VEGI174-treated group showed significant inhibition of tumor growth (p<0.05). The expression of E-cadherin was significantly higher in the VEGI174-treated group compared to the saline-treated group (p<0.01). However, the expression of N-cadherin and vimentin were reduced in the VEGI174-treated group. Conclusion: Our findings indicate that VEGI174 prevents progression and tumor metastasis through inhibiting EMT in RCC in vivo. This may provide a new approach for the treatment of RCC.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	International Institute of Anticancer Research (IIAR)
ISSN:	0250-7005
Funders:	the National Natural Science Foundation of China, grant No. 81372138 and Cancer Research Wales
Date of First Compliant Deposit:	15 January 2018
Date of Acceptance:	24 April 2017
Last Modified:	05 May 2023 00:02
URI:	https://orca.cardiff.ac.uk/id/eprint/103034

Citation Data

Cited 2 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item